Visualizing the US stock market: We put yesterday's stock market moves into some recent context

2/25/21 7:00PM

US stock markets fell almost 2.5% yesterday, as fears about rising inflation spread from the bond market into stocks. In more normal times, a fall of that magnitude would usually rank among the worst days in a year — but not since the pandemic. The fall yesterday is actually only the 23rd worst day since the start of 2020, and it is still nothing on the ~12% drop that happened on March 16th 2020 when panic gripped investors at the beginning of the pandemic.

‍Stocks only go up?

‍Tech stocks got hit particularly hard yesterday. Apple fell 3.5%, Facebook3.6%, Airbnb was down 9% and Tesla fell 8%. For retail investors that have piled into tech stocks since the start of the year, this probably came as a shock to the system after so many days in the green.

Whether yesterday proves to be just another minor hiccup on the unrelenting upward march that tech stocks have been on, or something more serious, is probably going to depend on the actual inflation data. Investors have been expecting higher inflation for a while — something we wrote about 2 weeks ago — but it's yet to really show up in a significant way; meaning that it's going to be all eyes on the next inflation data release (March 10th, bet you can't wait).

One stock that didn't go down yesterday was — you guessed it — GameStop. Much to the delight of traders on Reddit, GME shares gained another 18%, taking the stock back over $100, the highest it has been for a number of weeks but still a far cry from the $347 the shares closed at back in January.

Strive Pharmacy recently broke ground on a new facility in Mesa, Arizona. (Strive Pharmacy)

Before Hims’ GLP-1 pill fallout, its pharmacy partner was already drawing scrutiny from state regulators

Strive has already been probed over the timing of its GLP-1 compounding. Now, Arizona regulators are looking into complaints about ketamine misuse and improper distribution of prescription drugs.

J. Edward Moreno2/13/26

Claire Yubin Oh

The apex operator

2/13/26

SharkNinja hit an all-time high this week, as its killer growth streak continues

The viral appliance maker’s sales have more than quadrupled since 2018.

Surreal image of great white shark swimming in bedroom

Claire Yubin Oh

in this econemy?

2/12/26

Van Leeuwen, America’s fastest-growing dessert chain, is looking to expand abroad

The boutique ice cream chain is looking to open at least 300 new shops in South Korea over the next decade.

J. Edward Moreno

2/10/26

Hims built a boundary-pushing health business. Now the legal risks are catching up.

Hims is close to trading as if it never began selling GLP-1s.

Nate Becker2/7/26

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration.

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Hims & Hers Comms on X